TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32347684

Group type: EXPERIMENTAL
Intervention: Guidance document recommendations on diagnosis and treatment of LGG patients
Number of subjects: 0
Study: 37192722

Group type: EXPERIMENTAL
Intervention: Milk fat globule membrane + lactoferrin
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control
Number of subjects: 292
Study: 33523702

Group type: EXPERIMENTAL
Intervention: Anodal tDCS delivered at Fp3 (10 mins at 1.5 mA)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (using a Face-Matching task)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at Fp3
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 168
Study: 32693427

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 15
Study: 35946416

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + COPD Education (COPD‐ED)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: COPD Education (COPD‐ED) + Attention Control (AC)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Attention Control (AC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Attention Control (AC) only
Number of subjects: 109
Study: 34454260

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32580188

Group type: EXPERIMENTAL
Intervention: Roxadustat (50 mg, n = 49; 70 mg, n = 50)
Number of subjects: 100
Study: 603021098

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M‐16V and Bifidobacterium longum BB536 supplementation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no bifidobacterial supplementation)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Bifidobacterium supplementation
Number of subjects: 166
Study: 33860689

Group type: EXPERIMENTAL
Intervention: Online ostracism
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: In-person ostracism
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 54
Study: 32433262

Group type: EXPERIMENTAL
Intervention: Baseline estradiol (E2) levels
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: Baseline estrone (E1) levels
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: E2 levels by BMI < 25
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: E2 levels by BMI > 30
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: E1 levels by BMI < 25
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: E1 levels by BMI > 30
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: Correlation between E2 and E1
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: Variation in E2 and E1 levels
Number of subjects: 4068
Study: 35134184

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg with exenatide-matched placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily 10 µg with dapagliflozin-matched placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and exenatide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dapagliflozin-exenatide
Number of subjects: 64
Study: 33819172

Group type: EXPERIMENTAL
Intervention: Intervention group (testing for STIs and providing information on treatment facilities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 36152041

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 6919

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6919
Study: 33143690

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine (vaccinated group)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Unvaccinated (control group)
Number of subjects: 2800
Study: 35656456

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 0
Study: 32111318

Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg) with positive control (PC) diet
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg) with negative control (NC) diet
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Positive control (PC) without phytase
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Coarse limestone with PC or NC diet
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Phytase with coarse limestone
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Negative control (NC) without phytase
Number of subjects: 1512
Study: 32264850

Group type: EXPERIMENTAL
Intervention: Fourier domain optical coherence tomography (OCT) measurements of macular thickness
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 116
Study: 34284006

Group type: EXPERIMENTAL
Intervention: Electrical Pudendal Nerve Stimulation (EPNS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT) plus Transanal Electrical Stimulation (TES)
Number of subjects: 96
Study: 32492096

Group type: EXPERIMENTAL
Intervention: Vitamin D and omega-3 fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35298223

Group type: EXPERIMENTAL
Intervention: Prosocial behavior (purchasing COVID-19-related items for others)
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Prosocial behavior (purchasing COVID-19-unrelated items for others)
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Proself behavior (purchasing COVID-19-related items for themselves)
Number of subjects: 1623
Study: 35807803

Group type: EXPERIMENTAL
Intervention: Experimental milk-based formula (EF) containing five HMOs (5.75 g/L; 2′‐FL, 3‐FL, LNT, 3′‐SL and 6′‐SL)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control milk-based formula (CF)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Experimental milk-based formula (EF)
Number of subjects: 363
Study: 32536111

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 17
Study: 35595781

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (factor-Xa inhibitor)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Clinical model including NT-proBNP
Number of subjects: 940
Study: 34654496

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glass fiber-reinforced composite crowns (GFRC)
Number of subjects: 30
Study: 32249513

Group type: EXPERIMENTAL
Intervention: 10-step stair ascent test under dual task condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TUG test under dual task condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TUG test under single task condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10-m walking test under dual task condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10-m walking test under single task condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fear of falling and number of falls in the last year
Number of subjects: 38
Study: 33108622

Group type: EXPERIMENTAL
Intervention: Dociparstat sodium (DSTAT) added to standard of care
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 35337393

Group type: EXPERIMENTAL
Intervention: Isotonic tongue exercises (SG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No isotonic tongue exercises (CG)
Number of subjects: 40
Study: 34852148

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34856038

Group type: EXPERIMENTAL
Intervention: Iodoform-based paste (Guedes-Pinto - GP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Calcium hydroxide and iodoform paste (CaOH/Iodof paste; Vitapex®)
Number of subjects: 61
Study: 35903280

Group type: EXPERIMENTAL
Intervention: Exercise instructions from physical therapists for 30 min at baseline (week 0) and at week 4
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise instructions from physical therapists
Number of subjects: 36
Study: 33491327

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32306076

Group type: EXPERIMENTAL
Intervention: TIL + IL2
Number of subjects: 49

Group type: COMPARATOR
Intervention: Abstention
Number of subjects: 49
Study: 33175088

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 33615563

Group type: EXPERIMENTAL
Intervention: Minimal-access pyeloplasty (laparoscopic, with or without robotic assistance)
Number of subjects: 116
Study: 35412603

Group type: COMPARATOR
Intervention: Japanese encephalitis (JE) vaccine
Number of subjects: 61654
Study: 34044124

Group type: EXPERIMENTAL
Intervention: adapted BWL (aBWL)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: aBWL + self‐determination theory (aBWL+SDT)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: aBWL + behavioral economics (aBWL+BE)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 381
Study: 32767038

Group type: EXPERIMENTAL
Intervention: Voltaic arc dermabrasion (plasma exeresis technique)
Number of subjects: 45
Study: 33339762

Group type: EXPERIMENTAL
Intervention: Community care setting (WIC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Clinical care setting (primary care providers)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Weight-for-length z scores
Number of subjects: 129
Study: 33385738

Group type: EXPERIMENTAL
Intervention: Concomitant asthma, rhinitis, and eczema
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Asthma and rhinitis
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Allergic sensitization
Number of subjects: 1103
Study: 32339370

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membrane
Number of subjects: 27

Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral and resorbable collagen membrane
Number of subjects: 27
Study: 35796651

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus saline infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment + GIP(3‐30)NH2
Number of subjects: 12
Study: 32079912

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Caffeine (CAF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) alone
Number of subjects: 24
Study: 35437156

Group type: EXPERIMENTAL
Intervention: Filtek™ Bulk Fill Posterior
Number of subjects: 120

Group type: COMPARATOR
Intervention: Filtek™ Supreme XTE
Number of subjects: 120
Study: 32940683

Group type: EXPERIMENTAL
Intervention: Preparation for dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preparation for conservative care
Number of subjects: 0
Study: 35460085

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ordinary yogurt
Number of subjects: 90
Study: 32083593

Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 34
Study: 36050542

Group type: EXPERIMENTAL
Intervention: One planned, structured, telephone follow-up the day after discharge
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: As B but with additional telephone follow-up once weekly for 6 weeks
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: As C but with oriented coaching telephone follow-up on all occasions
Number of subjects: 525

Group type: COMPARATOR
Intervention: No telephone follow-up (control group)
Number of subjects: 525
Study: 34797217

Group type: EXPERIMENTAL
Intervention: High mindfulness
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low mindfulness
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 68

Group type: COMPARATOR
Intervention: No stress
Number of subjects: 68
Study: 36398460

Group type: EXPERIMENTAL
Intervention: Dietary weight management programme
Number of subjects: 170

Group type: COMPARATOR
Intervention: Best-practice care
Number of subjects: 170
Study: 32897344

Group type: EXPERIMENTAL
Intervention: Out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group)
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Placebo (out-of-hospital and in-hospital)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Tranexamic acid groups (combined)
Number of subjects: 1280
Study: 34772900

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LL-BFR) resistance training (20%-35% 1RM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-load (HL) resistance training (70%-85% 1RM)
Number of subjects: 29
Study: 33978903

Group type: EXPERIMENTAL
Intervention: Tactics of Optimized Potential (TOP) program
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Heart Coherence (HC) program
Number of subjects: 180
Study: 32323192

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (OD) or 15 mg OD if creatinine clearance was 30-49 mL/min
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg and 20 mg OD dosages
Number of subjects: 14264
Study: 35112328

Group type: EXPERIMENTAL
Intervention: LY01008 (3 mg/kg)
Number of subjects: 102
Study: 33397855

Group type: COMPARATOR
Intervention: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml, administered every 15 days for 3 months (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml plus oral colchicine 0.5mg twice daily for 3 months (Group B)
Number of subjects: 60
Study: 36107416

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1070
Study: 32724076

Group type: EXPERIMENTAL
Intervention: Sitagliptin therapy for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DPP4 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: High fat feeding
Number of subjects: 0
Study: 35935797

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) in group B
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Flupentixol and melitracen (FM) + acid-suppressive therapy (AST) in group B
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) in group E
Number of subjects: 362

Group type: COMPARATOR
Intervention: H2 receptor antagonists (H2RAs) in group D
Number of subjects: 362

Group type: COMPARATOR
Intervention: H2 receptor antagonists (H2RAs) in group A
Number of subjects: 362

Group type: COMPARATOR
Intervention: Acid-suppressive therapy (AST) in group C
Number of subjects: 362
Study: 33441418

Group type: EXPERIMENTAL
Intervention: U-TURN group (1-year supervised exercise and individualized dietary counseling)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 98
Study: 35772461

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 0
Study: 34033123

Group type: EXPERIMENTAL
Intervention: Subsequent pregnancies after hyperemesis gravidarum
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Recurrence of hyperemesis gravidarum in subsequent pregnancies
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Termination of pregnancy due to recurrent hyperemesis gravidarum
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Not getting pregnant again due to hyperemesis gravidarum
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Predictive factors for weight loss due to recurrent hyperemesis gravidarum
Number of subjects: 73
Study: 32220194

Group type: EXPERIMENTAL
Intervention: Occlusion group (temporary occlusion of the root of the splenic artery)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-occlusion group (direct dissection without occlusion)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (tumor diameter ≤3 cm)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (tumor diameter >3 cm)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Occlusion group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-occlusion group
Number of subjects: 54
Study: 35722182

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated observation for 12 weeks
Number of subjects: 30
Study: 34511288

Group type: EXPERIMENTAL
Intervention: Automated oxygen control with the CLiO2 algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual control of oxygen titration
Number of subjects: 0
Study: 34077887

Group type: EXPERIMENTAL
Intervention: 1.5 g EPA + 1.0 g DHA daily (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mineral oil daily (n = 18)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EPA+DHA group
Number of subjects: 32
Study: 33999760

Group type: EXPERIMENTAL
Intervention: Modified information letters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified information letters and questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted information flyer
Number of subjects: 0
Study: 33881774

Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no earplugs and eye masks)
Number of subjects: 100
Study: 33649058

Group type: EXPERIMENTAL
Intervention: Methoxyflurane administered by inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (Methoxyflurane and Morphine)
Number of subjects: 0
Study: 32195952

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Massage chair therapy
Number of subjects: 56
Study: 616631332

Group type: COMPARATOR
Intervention: Simulated sham lithium plasma concentrations
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Actual lithium plasma concentrations in treatment arm
Number of subjects: 257
Study: 34536349

Group type: EXPERIMENTAL
Intervention: BBIBP-CorV vaccine (2 ?g, 4 ?g, or 8 ?g)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1008
Study: 32899074

Group type: EXPERIMENTAL
Intervention: 3 doses of intravenous dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 dose of intravenous dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 doses of intravenous dexamethasone
Number of subjects: 0
Study: 34842957

Group type: EXPERIMENTAL
Intervention: PI-QUAL v1 tool for evaluating prostate MRI quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI-QUAL tool development
Number of subjects: 0
Study: 34536763

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective sensory nerve blockade (SSNB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intraoperative periarticular infiltration (PAI)
Number of subjects: 72
Study: 36109038

Group type: EXPERIMENTAL
Intervention: Standard of care (MIC guided)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MBEC-guided antibiotic regimen
Number of subjects: 64
Study: 32241319

Group type: EXPERIMENTAL
Intervention: Choice-enhancing language ('the choice is yours')
Number of subjects: 174

Group type: COMPARATOR
Intervention: Choice-restricting language ('you must')
Number of subjects: 174
Study: 32353246

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 476
Study: 35954320

Group type: EXPERIMENTAL
Intervention: Arm A (treatment group)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Arm B (treatment group)
Number of subjects: 306
Study: 33184097

Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone (AAP)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: UCP (combined with PSA-non-response)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: UCP
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: crPFS
Number of subjects: 736
Study: 33219016

Group type: EXPERIMENTAL
Intervention: Nivolumab (nivo)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Everolimus (evero)
Number of subjects: 223
Study: 33210509

Group type: EXPERIMENTAL
Intervention: Combination of somatostatin analogues and glucocorticoids in high risk group (25 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Somatostatin analogue in control subgroup of high risk group (13 patients)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Somatostatin analogue in low risk group (18 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No specific prophylaxis in control subgroup of low risk group (22 patients)
Number of subjects: 78
Study: 35057430

Group type: EXPERIMENTAL
Intervention: Early eating window (6:48 ± 0:21 AM)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Late eating window (8:11 ± 1:05 AM)
Number of subjects: 97